← Research library

Weekly thymopentin by intramuscular or intravenous injection in rheumatoid arthritis

Comparison in people · 1982

What was studied
92 entrants across two comparisons. The double-blind study enrolled 21 patients on 1 mg intramuscular thymopentin and 20 on saline. A separate open study enrolled 51 patients on 50 mg intravenously and reused the 20 saline controls. At six months, 15, 16 and 44, respectively, were evaluable.
Main finding
Six-month global response · Marked improvement was reported in 18% on 50 mg IV, 6% on 1 mg IM and 0% on saline. The full global-response distribution favored IV treatment over saline (p=0.005) and over 1 mg IM (p=0.030).

Reported findings and study design

Reported findings

Weekly injections for six months with assessments at baseline, three months and six months. The intramuscular arm and saline placebo were masked. The intravenous arm was open. Patients could continue analgesics and anti-inflammatory medication, with corticosteroids limited to the equivalent of 10 mg prednisolone per day.

Population or model 92 entrants across two comparisons. The double-blind study enrolled 21 patients on 1 mg intramuscular thymopentin and 20 on saline. A separate open study enrolled 51 patients on 50 mg intravenously and reused the 20 saline controls. At six months, 15, 16 and 44, respectively, were evaluable.

Dose, route and schedule

Weekly injections for six months with assessments at baseline, three months and six months. The intramuscular arm and saline placebo were masked. The intravenous arm was open. Patients could continue analgesics and anti-inflammatory medication, with corticosteroids limited to the equivalent of 10 mg prednisolone per day.

Protocol source ↗ · Original full text, pp. 441–443 and Tables 1–3.

Results · Original full text, pp. 441–443 and Tables 1–3.
MeasureResultComparison, timing and statistics
Six-month global responseMarked improvement was reported in 18% on 50 mg IV, 6% on 1 mg IM and 0% on saline. The full global-response distribution favored IV treatment over saline (p=0.005) and over 1 mg IM (p=0.030).
Intramuscular comparisonThe 1 mg IM arm did not significantly differ from saline on the six-month global response.
SafetyNo adverse-event withdrawals. One fever was reported on 1 mg IM, and two rashes, one herpes zoster case and one diarrhea case on 50 mg IV. Attribution was uncertain.
Six-month global response
Six-month global response
OutcomeSaline (n=20)1 mg IM (n=18)50 mg IV (n=44)
Marked improvement0%6%18%
Moderate improvement55%55%64%
Deterioration25%22%18%
Withdrawal for lack of effect20%17%0%

The denominators in Table 3 include withdrawals for lack of effect. The two comparisons share one saline group.

Selected median clinical measures at baseline, month 3 and month 6
Selected median clinical measures at baseline, month 3 and month 6
OutcomeSaline1 mg IM50 mg IV
Ritchie tenderness index24.5 → 21 → 22.526 → 23 → 2121 → 13 → 11
Tender joints14 → 12.5 → 12.514 → 14 → 1413 → 10 → 8
Swollen joints8.5 → 7.5 → 87 → 6 → 68 → 6 → 6
Pain, mm60.5 → 55.5 → 4565 → 58 → 6056 → 42 → 33
Morning stiffness, min60 → 45 → 3060 → 60 → 3060 → 30 → 30
Erythrocyte sedimentation rate, mm/h44.5 → 54 → 4535 → 31.5 → 3748 → 46 → 44

Table 2 tests within-arm changes. Sedimentation rate did not change significantly in any arm.

The 50 mg IV arm used the same controls as the intramuscular study and was unblinded. The Veys and Thrower groups shared London investigators, so any patient overlap between their 1982 reports remains unresolved.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The 50 mg IV arm used the same controls as the intramuscular study and was unblinded. The Veys and Thrower groups shared London investigators, so any patient overlap between their 1982 reports remains unresolved.

Source details

Original full text, pp. 441–443 and Tables 1–3.

Sources checked

Added to the library

Citation

Human comparative studyFull text available

E. M. Veys, E. C. Huskisson, M. Rosenthal, T. L. Vischer, H. Mielants, P. A. Thrower, J. Scott, H. Ott, H. Scheijgrond, J. Symoens. Weekly thymopentin by intramuscular or intravenous injection in rheumatoid arthritis Annals of the Rheumatic Diseases 41(5), 441–443

Study source ↗ · DOI 10.1136/ard.41.5.441 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards